Clearmind Medicine (NASDAQ:CMND) Announces Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) released its earnings results on Wednesday. The company reported ($0.11) EPS for the quarter, Zacks reports.

Clearmind Medicine Stock Performance

Shares of NASDAQ CMND traded down $0.02 during midday trading on Friday, hitting $1.47. The company had a trading volume of 7,171 shares, compared to its average volume of 233,085. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $1.41. Clearmind Medicine has a twelve month low of $0.95 and a twelve month high of $2.30.

About Clearmind Medicine

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.